Huntington Bancshares Incorporated · HBAN · FY2026 Q2 · Calendar Q3 2026
Huntington Bancshares Q2 2026: Strong Organic Growth, EPS Miss on Deposit Cost Pressure
Huntington Bancshares delivered strong Q2 2026 organic growth, with 8.6% sequential loan growth and 9.2% sequential deposit growth, alongside the successful completion of the Cadence systems conversion in just 235 days. Fee revenues expanded 10-46% year-over-year across payments, wealth management, and capital markets. However, EPS of $0.33 missed the consensus estimate of $0.36 by 8.0%, driven by rising deposit costs pressuring net interest margin. Revenue of $2.857 billion modestly exceeded the $2.838 billion estimate by 0.7%. Management maintained full guidance, reaffirming 2027 targets of 18-19% ROTCE and $1.90-$1.93 EPS, with share repurchases scaling to $1.1-1.2 billion in 2027. The stock fell 3.5% on an abnormal basis following the report, with continued negative drift of -3.2% in subsequent sessions on 3.2x baseline volume. The bullish score improved from 78 to 82…
Company context
Snapshot as of publicationHuntington Bancshares Incorporated, established in Columbus, Ohio, in 1866, operates as the bank holding company for The Huntington National Bank, providing a comprehensive suite of commercial, consumer, and mortgage banking services across the United States. Its operations are organized into four key segments. The Consumer and Business Banking segment offers essential financial products to individuals and small businesses, including checking, savings, money market, and certificate of deposit accounts, along with credit cards, various loans, and investment opportunities. This segment also facilitates mortgages, insurance, interest rate risk protection, foreign exchange, and provides convenient access through ATMs, online, mobile, and telephone banking.…
Earnings scorecard
Reported versus consensusEarnings History
Analyst 52W Price Targets
Latest persisted target per named analyst; persisted previous close from FN2's market snapshot as of Jul 30, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Truist Securities | Buy | Buy | Maintain | Jul 28, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Jul 28, 2026 |
| B of A Securities | Neutral | Buy | Downgrade | Jul 27, 2026 |
| Stephens & Co. | Equal Weight | Equal Weight | Maintain | Jul 24, 2026 |
| Morgan Stanley | Equal Weight | Overweight | Downgrade | Jul 24, 2026 |
| Baird | Outperform | Outperform | Maintain | Jul 24, 2026 |
| UBS | Buy | Buy | Maintain | Jul 7, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Jul 6, 2026 |
| Jefferies | Hold | Buy | Downgrade | Jul 6, 2026 |
| DA Davidson | Buy | Buy | Maintain | Mar 16, 2026 |
| Keefe, Bruyette & Woods | Market Perform | Market Perform | Maintain | Jan 23, 2026 |
| Barclays | Equal Weight | Equal Weight | Maintain | Jan 5, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | Dec 19, 2025 |
| Piper Sandler | Underweight | Underweight | Maintain | Dec 10, 2025 |
| TD Cowen | Buy | Buy | Maintain | Oct 20, 2025 |
| Raymond James | Strong Buy | Strong Buy | Maintain | Oct 20, 2025 |
| Wolfe Research | Outperform | Peer Perform | Upgrade | Jul 3, 2025 |
| Citigroup | Buy | Buy | Maintain | Jul 2, 2025 |
| Goldman Sachs | Buy | Buy | Maintain | Nov 26, 2024 |
| Argus Research | Buy | Buy | Maintain | Jul 22, 2024 |
| Wedbush | Neutral | Neutral | Maintain | Apr 21, 2023 |
| Deutsche Bank | Hold | Hold | Maintain | Sep 12, 2022 |
| BMO Capital | Market Perform | Market Perform | Maintain | Jul 24, 2020 |
| Nomura | Neutral | Neutral | Maintain | Apr 7, 2020 |
| CFRA | Hold | Hold | Maintain | Apr 6, 2020 |
| Bank of America | Neutral | Buy | Downgrade | Oct 25, 2019 |
| Macquarie | Underperform | Neutral | Downgrade | Jul 12, 2019 |
| Argus | Hold | Hold | Maintain | May 31, 2019 |
| Sandler O'Neill | Hold | Buy | Downgrade | Nov 29, 2018 |
| Hilliard Lyons | Buy | Neutral | Upgrade | Feb 9, 2018 |
| Bernstein | Outperform | Market Perform | Upgrade | Sep 14, 2017 |
| JMP Securities | Perform | Market Perform | Maintain | Aug 31, 2017 |
| PiperJaffray | Overweight | Neutral | Upgrade | Aug 11, 2017 |
| FBR Capital | Market Perform | Outperform | Downgrade | Oct 11, 2016 |
| Sterne Agee CRT | Buy | Neutral | Upgrade | Apr 6, 2016 |
| Sterne Agee | Buy | Neutral | Upgrade | Apr 6, 2016 |
| Credit Suisse | Neutral | Neutral | Maintain | Jan 22, 2016 |
| Guggenheim | Buy | Neutral | Upgrade | Aug 28, 2015 |
| CLSA | Underperform | Underperform | Maintain | Jul 8, 2015 |
| SunTrust Robinson Humphrey | Neutral | Neutral | Maintain | Jun 29, 2015 |
| Canaccord Genuity | Hold | Buy | Downgrade | May 11, 2015 |
| Keefe Bruyette & Woods | Market Perform | Outperform | Downgrade | Apr 24, 2015 |
| Miller Tabak | Buy | Hold | Upgrade | Mar 9, 2015 |
| Portales Partners | Sector Perform | Underperform | Upgrade | Jul 21, 2014 |
| ISI Group | Neutral | Neutral | Maintain | Oct 7, 2013 |
| Compass Point | Neutral | Buy | Downgrade | Apr 18, 2013 |
| Evercore Partners | Overweight | Equal Weight | Upgrade | Dec 19, 2012 |
| Bank oferica | Buy | Buy | Maintain | May 9, 2012 |
Named analyst price targets
Upside is calculated against the persisted previous close $16.84. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| Truist Financial | Analyst unavailable | $20 | $17.24 | +18.8% | Jul 28, 2026 |
| Robert W. Baird | David George | $21 | $17.4 | +24.7% | Jul 24, 2026 |
| Stephens | Analyst unavailable | $19 | $17.4 | +12.8% | Jul 24, 2026 |
| Jefferies | Analyst unavailable | $18 | $17.4 | +6.9% | Jul 23, 2026 |
| UBS | Analyst unavailable | $22 | $18.03 | +30.6% | Jul 7, 2026 |
| Evercore ISI | John Pancari | $21 | $17.76 | +24.7% | Jul 6, 2026 |
| Jefferies | Analyst unavailable | $19 | $17.86 | +12.8% | Jul 6, 2026 |
| Morgan Stanley | Analyst unavailable | $21 | $17.81 | +24.7% | Jun 29, 2026 |
| Evercore ISI | Analyst unavailable | $20 | $17.21 | +18.8% | Jun 12, 2026 |
| Piper Sandler | Analyst unavailable | $18 | $16.62 | +6.9% | Apr 23, 2026 |
| Robert W. Baird | Analyst unavailable | $20 | $16.12 | +18.8% | Mar 9, 2026 |
| UBS | Analyst unavailable | $21 | $19.08 | +24.7% | Feb 4, 2026 |
| National Bank | Manan Gosalia | $21 | $18.39 | +24.7% | Feb 4, 2026 |
| RBC Capital | Analyst unavailable | $21 | $17.8 | +24.7% | Jan 12, 2026 |
| Wolfe Research | Analyst unavailable | $21 | $18.1 | +24.7% | Jan 7, 2026 |
| Goldman Sachs | Ryan Nash | $21 | $17.99 | +24.7% | Jan 6, 2026 |
| Barclays | Analyst unavailable | $20 | $17.48 | +18.8% | Jan 5, 2026 |
| RBC Capital | Analyst unavailable | $20 | $17.62 | +18.8% | Dec 19, 2025 |
| Piper Sandler | Analyst unavailable | $16 | $17 | -5.0% | Dec 10, 2025 |
| Evercore ISI | John Pancari | $18 | $15.97 | +6.9% | Oct 21, 2025 |
| Morgan Stanley | Analyst unavailable | $23 | $17.42 | +36.6% | Sep 29, 2025 |
| Argus Research | Kevin Heal | $17 | $14.46 | +1.0% | Apr 25, 2025 |
| Truist Financial | Brian Foran | $21 | $16.55 | +24.7% | Jan 21, 2025 |
| Citigroup | Keith Horowitz | $18 | $15.36 | +6.9% | Oct 21, 2024 |
| Piper Sandler | Scott Siefers | $15 | $15.43 | -10.9% | Oct 18, 2024 |
| Morgan Stanley | Manan Gosalia | $18 | $13.75 | +6.9% | Aug 5, 2024 |
| Robert W. Baird | David George | $15 | $15.06 | -10.9% | Jul 26, 2024 |
| Argus Research | Kevin Heal | $16 | $15.01 | -5.0% | Jul 22, 2024 |
| RBC Capital | Jon Arfstrom | $17 | $14.86 | +1.0% | Jul 22, 2024 |
| Morgan Stanley | Manan Gosalia | $16 | $14.8 | -5.0% | Jul 22, 2024 |
| D.A. Davidson | Peter Winter | $17.5 | $15.01 | +3.9% | Jul 22, 2024 |
| Stephens | Terry McEvoy | $16 | $15.01 | -5.0% | Jul 22, 2024 |
| Piper Sandler | Scott Siefers | $11.5 | $12.34 | -31.7% | Jun 14, 2024 |
| Piper Sandler | Scott Siefers | $13.5 | $12.77 | -19.8% | Jun 10, 2024 |
| Jefferies | Ken Usdin | $16 | $13.6 | -5.0% | Apr 8, 2024 |
| Stephens | Terry McEvoy | $15 | $13.95 | -10.9% | Apr 1, 2024 |
| UBS | Erika Naharian | $15 | $12.72 | -10.9% | Feb 14, 2024 |
| D.A. Davidson | Analyst unavailable | $15 | $14 | -10.9% | Dec 21, 2022 |
| J.P. Morgan | Analyst unavailable | $14.5 | $14.54 | -13.9% | Dec 13, 2022 |
| Morgan Stanley | Analyst unavailable | $19 | $15.46 | +12.8% | Dec 5, 2022 |
| Raymond James | Analyst unavailable | $18 | $14.1 | +6.9% | Apr 22, 2022 |
| RBC Capital | Jon Arfstrom | $19 | $15.03 | +12.8% | Jan 21, 2022 |
| Barclays | Jason Goldberg | $17 | $15.64 | +1.0% | Jan 3, 2022 |
| Stephens | Terry McEvoy | $17.5 | $15.55 | +3.9% | Nov 9, 2021 |
| Goldman Sachs | Ryan Nash | $18 | $14.27 | +6.9% | Aug 18, 2021 |
| KBW | David Konrad | $15 | $13.56 | -10.9% | Jul 6, 2021 |
Track every rating change on HBAN the moment it posts. Free to start.
Start freeMarket reaction
prior-close to event-session closeFollow HBAN with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeTranscript intelligence
What changed
Bullish score improved from 78 in Q1 to 82 in Q2. The Cadence systems conversion was completed in 235 days, ahead of the June target referenced in Q1, with deposits actually growing during the conversion weekend. Organic growth accelerated with 8.6% sequential loan growth and 9.2% sequential deposit growth. Fee revenue growth remained strong at 10-46% year-over-year. The EPS miss of $0.33 versus $0.36 consensus was a negative shift, driven by deposit cost pressure on net interest margin. The stock reacted negatively with a 3.5% abnormal decline and -3.2% subsequent drift on 3.2x baseline volume. Regulatory focus shifted from Basel III Endgame capital optimization in Q1 to CCAR stress test results in Q2. Share repurchase plans were scaled up from $550 million in 2026 to $1.1-1.2 billion targeted for 2027 under the $3 billion evergreen authorization.
Guidance delta
Guidance was maintained for the second consecutive quarter. Q1 2026 had seen NIM outlook revised down to the high 3.20% range while fee-income growth guidance was raised to 31-33%. Q2 brought no new guidance changes; management reaffirmed 2027 targets of 18-19% ROTCE and $1.90-$1.93 EPS. Share repurchase plans were scaled up from $550 million in 2026 to $1.1-1.2 billion targeted for 2027 under the $3 billion evergreen authorization announced in Q1.
Key takeaways
- Q2 organic loan growth of 8.6% sequential and deposit growth of 9.2% sequential demonstrate strong core franchise momentum.
- Cadence systems conversion completed in 235 days, ahead of schedule, with deposits growing during the conversion weekend -- a rare outcome for bank integrations.
- On track for $365 million in cost synergies by Q4 and over $1 billion in new pipeline revenue from cross-selling to acquired customers.
- Fee revenues grew 10-46% year-over-year across payments, wealth management, and capital markets, driving a diversified revenue flywheel.
- EPS of $0.33 missed the $0.36 consensus estimate by 8.0%; revenue of $2.857 billion modestly beat the $2.838 billion estimate by 0.7%.
- Guidance unchanged; 2027 ROTCE target of 18-19% and EPS of $1.90-$1.93 reaffirmed.
Management priorities
- Ramp up marketing spend in the Cadence footprint to accelerate digital deposit acquisition.
- Continue branch expansions in the Carolinas, Colorado, and Chicago.
- Further integrate and cross-sell to Cadence customers across payments, wealth, and treasury services.
- Maintain expense-reduction program targeting over 1.5% baseline OPEX reduction.
- Execute additional share repurchases of $1.1-1.2 billion in 2027.
Related earnings events
Financial ServicesSources
- Earnings call transcript and parsed analysis · 2026-07-23T18:04:23.772433+00:00
- FN2 earnings calendar · 2026-07-30T01:23:13.872335+00:00
- Polygon adjusted daily market bars · 2026-07-30T08:31:59.281007+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-07-30T08:31:59.278391+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated . For educational purposes only; not investment advice.